



Semintra[®] (telmisartan) — designed with cats and owners in mind

The first and only liquid solution for the management of chronic kidney disease in cats

Semintra[®] (telmisartan) 4 mg/ml oral solution for cats. Indication: Reduction of proteinuria in chronic kidney disease (CKD) in cats. Contraindications: The safety of Semintra has not been established in breeding, pregnant or lactating cats. Do not use during pregnancy or lactation. Do not use in cases of hypersensitivity to the active substance or to any of the excipients. This text is based on the summary of product characteristics (dated 2018-12-07). More information is available on the European Medicines Agency website, at: https://www.ema.europa.eu/en/documents/product-information/semintra-epar-product-information_en.pdf. For animal treatment only. To be supplied only on veterinary prescription. Reporting adverse events is important. Reports should be sent to the marketing authorization holder or the National Organization for Medicines via the national reporting system. Boehringer Ingelheim Vetmedica GmbH, 55216 Ingelheim/Rhein, GERMANY. EU/2/12/146/001-002. Semintra is a registered trademark of Boehringer Ingelheim Vetmedica GmbH. ©2022. All rights reserved. 601750

Semintra
telmisartan